Prospective Study on the Efficacy and Safety of 2 Week or 3 Week Xelox Regimen for Adjuvant Chemotherapy in CRC

Inclusion Criteria: * Carcinoma of the intestine confirmed histologically or cytologically * Radical surgical resection was performed after diagnosis and the post operative stages were high-risk II or III patients * The ECOG PS score less than or equal to 2 points * No chemotherapy of any kind has been performed in the past * Neutrophils acuity 1.5x10e9/L, platelets more than 100x10e9/L, college blood red protein more than 9g/dL * liver function transaminase is less than or equal to 2.5 ULN, alkaline phosphatase is less than 2.5 ULN, and total bilirubin is less than 1.5 ULN Exclusion Criteria: * Patients with unresectable CRC * Patients who have any form of chemotherapy before * Participating in or having participated in clinical studies of other drug * Patients have second primary malignant tumors of have other malignant tumors in the past five years * There is evidence of allergic reaction to drugs in this study * A history of ischemic heart disease in the past 1 year or patients with high risk factors for heart failure, or uncontrolled arrhythmias * Severe active inflammation, including tuberculosis and HIV * Long-term immunization or hormone therapy, except hormone replacement therapy at physiological dose * Drug or alcohol addiction * Get pregnant or breastfeed * The investigator considers that the patient is not suitable for this clinical study due to any clinical or laboratory abnormalities or compliance problems